September 29, 2020
Otsuka Pharmaceutical on September 28 submitted a new drug application for its atopic dermatitis treatment difamilast in Japan. Previously known with the development code OPA-15406, difamilast is a topical phosphodiesterase 4 (PDE4) inhibitor originated by Otsuka. It is expected to...read more